We are updating the osteoporosis guideline to bring all NICE recommendations into one comprehensive resource. The revised guidance will be delivered in two parts:
Part 1: will cover identifying adults who should be assessed for fragility fracture risk, methods of risk assessment, identifying vertebral fractures, treatment criteria and repeat risk assessment (timing and methods) for people not receiving treatment.
Part 2: will cover risk assessment for people with a learning disability, treatment (pharmacological, exercise and calcium and vitamin D), monitoring of treatment and treatment pauses, incorporating recommendations from a new Multiple Technology Appraisal (MTA) to create a single set of pharmacological treatment guidelines.
The Stakeholder consultation on Part 1 and the consultation on the MTA scope runs from 13 January to 23 February 2026.
You can now comment on this draft scope. The scope defines what the guideline will (and will not) cover.
The consultation closes on Thursday, 01 December 2022 at 5pm
How to comment
1. Register your organisation
Your organisation needs to be registered as a stakeholder before we can accept comments.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
2. Read the consultation documents
Background documents
3. Make your comments
- You must use the comments form
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another registered organisation, send a joint response.
Whilst submitting your comments please could you consider the following questions:
- Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline?
- Do you agree with the decision to exclude non-pharmacological interventions (beyond Vitamin D and Calcium) from this guideline? Please explain the reasons for your response.
4. Email the form to us
Email: Osteoporosis@nice.org.uk
Deadline: Thursday, 01 December 2022 at 5pm